Suppr超能文献

文莱达鲁萨兰国的乳腺癌治疗方式、治疗延误及生存率

Breast cancer treatment modalities, treatment delays, and survival in Brunei Darussalam.

作者信息

Yean Ang Woan, Leong Elvynna, King Ong Sok, Mohamad Zulkhairi

机构信息

Faculty of Science, Universiti Brunei Darussalam, Jln Tungku Link, Bandar Seri Begawan, Brunei Darussalam.

PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Jln Tungku Link, Bandar Seri Begawan, Brunei Darussalam.

出版信息

BMC Cancer. 2025 Mar 20;25(1):510. doi: 10.1186/s12885-025-13861-2.

Abstract

INTRODUCTION

Breast cancer remains a leading cause of cancer-related mortality globally. This study aims to examine the demographic variables and effects of different treatment modalities and treatment delays on overall and relative survival rates of breast cancer patients in Brunei Darussalam.

METHODS

This retrospective study analysed data from the Brunei Darussalam Cancer Registry on breast cancer cases diagnosed and treated between 2013 and 2022. Statistical analyses included descriptive statistics to characterise the study population, Kaplan-Meier estimates to compare survival curves of different groups, Log rank tests to determine significant differences in survival rates among groups, and Cox Proportional Hazard (PH) models to estimate hazard ratios (HRs) and identify predictors of survival outcomes. Overall survival (OS) and relative survival (RS) rates were calculated.

RESULTS

Out of the 431 women treated for breast cancer, the majority were diagnosed at the regional stage (45.7%), with 39.0% at the localised stage. Over half (55.4%) of the diagnoses occurred in women aged 40 to 59, while about a quarter (25.5%) were in the 60-69 age group. Surgery was the most common first-line treatment modality (55.9%), with a median time to treatment of 37 days, followed by chemotherapy (30.6%). More than half of the patients (62.9%) were treated within 60 days of diagnosis. Treatment varied by age and cancer stage, with younger patients more likely to undergo surgery and older patients more likely to receive chemotherapy or hormonal therapy. Survival rates were high for patients receiving only surgery (5-year RS: 98.7%, OS: 92.3%), and significant survival differences were found for cancer stage and treatment delay, with a HR of 2.5 for delays over 60 days. Multivariate analysis showed that patients with distant stage cancer had a significantly higher risk of death (HR = 15.3) compared to localised stage.

CONCLUSION

This study highlights the impact of treatment modalities and delays on breast cancer survival in Brunei Darussalam, emphasising the need for timely treatment to improve survival rates. Our findings suggest that ensuring breast cancer treatment initiation within two months post-diagnosis may enhance patient outcomes, supporting potential policy targets for timely access to care.

摘要

引言

乳腺癌仍是全球癌症相关死亡的主要原因。本研究旨在探讨文莱达鲁萨兰国乳腺癌患者的人口统计学变量、不同治疗方式及治疗延迟对总体生存率和相对生存率的影响。

方法

这项回顾性研究分析了文莱达鲁萨兰国癌症登记处2013年至2022年期间诊断和治疗的乳腺癌病例数据。统计分析包括描述性统计以描述研究人群特征、Kaplan-Meier估计以比较不同组的生存曲线、对数秩检验以确定组间生存率的显著差异,以及Cox比例风险(PH)模型以估计风险比(HR)并确定生存结果的预测因素。计算了总体生存率(OS)和相对生存率(RS)。

结果

在431例接受乳腺癌治疗的女性中,大多数在区域阶段被诊断(45.7%),局部阶段为39.0%。超过一半(55.4%)的诊断发生在40至59岁的女性中,而约四分之一(25.5%)在60 - 69岁年龄组。手术是最常见的一线治疗方式(55.9%),中位治疗时间为37天,其次是化疗(30.6%)。超过一半的患者(62.9%)在诊断后60天内接受治疗。治疗因年龄和癌症阶段而异,年轻患者更有可能接受手术,老年患者更有可能接受化疗或激素治疗。仅接受手术的患者生存率较高(5年RS:98.7%,OS:92.3%),并且在癌症阶段和治疗延迟方面发现了显著的生存差异,延迟超过60天的HR为2.5。多变量分析表明,与局部阶段相比,远处阶段癌症患者的死亡风险显著更高(HR = 15.3)。

结论

本研究强调了治疗方式和延迟对文莱达鲁萨兰国乳腺癌生存的影响,强调了及时治疗以提高生存率的必要性。我们的研究结果表明,确保在诊断后两个月内开始乳腺癌治疗可能会改善患者预后,支持及时获得治疗的潜在政策目标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0223/11924827/fad21d1bddf8/12885_2025_13861_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验